Outsourcing

Jan 23, 2018
By BioPharm International Editors
Paragon Bioservices will build a new cGMP facility in Maryland and expand its existing cGMP facility at the University of Maryland's BioPark.
Jan 16, 2018
By BioPharm International Editors
The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.
Jan 01, 2018
BioPharm International
The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.
Jan 01, 2018
BioPharm International
Recent investments show expansion activity in cell culture facilities.
Dec 19, 2017
By BioPharm International Editors
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
Dec 14, 2017
By BioPharm International Editors
Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical trials.
Dec 13, 2017
By BioPharm International Editors
The European Medicines Agency has granted Samsung BioLogics approval to manufacture a monoclonal antibody at the company’s second facility in Songdo, Incheon, South Korea.
Dec 08, 2017
By BioPharm International Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Dec 07, 2017
An increasing number of warning letters shows that FDA is observing more problems with pharmaceutical contract manufacturing.
Dec 06, 2017
By BioPharm International Editors
The contract research, development, and manufacturing organization has expanded API aseptic manufacturing capacity at its Valladolid, Spain, facility.
native1_300x100
lorem ipsum